583 results on '"Northfelt, Donald W."'
Search Results
2. Patient and nursing staff perspectives on automated scalp cooling (ASC) for chemotherapy-induced alopecia in breast cancer
3. A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)
4. Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors
5. Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
6. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
7. Trends over time in liquid biopsy testing in patients with metastatic breast cancer (MBC) across the Mayo Clinic enterprise.
8. Association of breast cancer risk, density, and stiffness: global tissue stiffness on breast MR elastography (MRE)
9. Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer
10. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
11. Characterizing Occult Nodal Disease Within a Clinically Node-Negative, Neoadjuvant Breast Cancer Population
12. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
13. PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
14. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer
15. Adaptive Randomization of Neratinib in Early Breast Cancer
16. Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
17. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer
18. Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study
19. N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer
20. A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer
21. Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy
22. Abstract 1921: Universal genetic testing for hereditary cancer syndromes in an under-represented minority population
23. Table S1 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
24. Figure S2 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
25. Supplementary Table S1 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
26. Supplementary Figure Legends from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
27. Supplementary Data from A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors
28. Supplementary Table 1 from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
29. Supplementary Tables S1 and S2 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
30. Supplementary Table 2 from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
31. Supplementary Material Legend from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
32. Supplementary Tables from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
33. Figure S4 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
34. Supplementary Figures 1 - 3, Tables 1 - 9 from Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437
35. Supplementary Figure S2 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
36. Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients
37. A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321
38. Additional file 1 of Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors
39. Does biomarker information impact breast cancer patients’ preferences and physician recommendation for adjuvant chemotherapy?
40. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway
41. Understanding feasibility and patient experiences with a ride share program to facilitate uninsured, Hispanic participation in clinical trials: A pilot survey study.
42. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study
43. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma
44. Integration of multi-omics data shows downregulation of mismatch repair, purin, and tubulin pathways in triple-negative chemotherapy-resistant breast tumors
45. Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine versus placebo in patients with residual disease post-neoadjuvant chemotherapy.
46. Posttransplant Lymphoproliferative Disorder: Otolaryngological Manifestations and Management
47. North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane
48. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy
49. Integration of multi-omics data shows downregulation of mismatch repair, purin, and tublin pathways in AR-negative triple-negative chemotherapy-resistant breast tumors
50. Pegylated-Liposomal Doxorubicin (Doxil®) in the Treatment of AIDS-Related Kaposi’s Sarcoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.